Standard BioTools has completed the sale of its Microfluidics business to healthcare-focused investment firm ARCHIMED. The business will operate as a standalone company called Biomark Scientific, with its existing team and products continuing under new ownership.
The announcement marks the close of the previously announced divestiture. It does not state the purchase price or provide details on the sale’s financial impact for Standard BioTools.
Key details
- Biomark Scientific will focus on genomic analysis tools. Its products include the Biomark platform, which supports high-throughput genomic workflows. The company describes its next-generation Biomark X9 as an automated system for PCR, qPCR and next-generation sequencing library preparation.
- The business will continue serving research institutions, public health laboratories and biobanks. It also plans to build its capabilities in genomics, clinical research and public health.
- ARCHIMED says it intends to support the business’s growth. The new owner plans to build on Biomark Scientific’s technology, expertise and customer relationships. The announcement does not specify the amount or form of any planned investment.
- The team and customer-facing operations are expected to continue. Biomark Scientific says it will retain the dedicated team and aim to maintain continuity of products and services for customers and partners.
- Luke Stewart has been appointed chief commercial officer of Biomark Scientific.
What changes for Standard BioTools
Standard BioTools no longer owns the Microfluidics business; it now sits within ARCHIMED as Biomark Scientific. The announcement does not provide a sale price or describe how the proceeds will be used.